Navigation Links
Huahai and Oncobiologics Create Broad Biosimilars Partnership
Date:5/8/2013

CRANBURY, N.J., May 8, 2013 /PRNewswire/ -- Oncobiologics, Inc. announced today that Zhejiang Huahai Pharmaceutical Co., Ltd and Oncobiologics have signed an alliance agreement for the development, manufacture and commercialization of biosimilar monoclonal antibody products.  The scope of the agreement includes exclusive commercialization by Huahai of four biosimilars developed by Oncobiologics and manufactured in China at a Huahai biologics facility for the China market, and will also establish a co-development and commercialization partnership for launching such biosimilars to more than 30 developed countries, including the U.S., E.U., Japan, Canada and Australia.  The partnership will seek local partners to drive commercialization in those 30 countries.

The four biosimilars are generic versions of Humira®, Rituxan®, Avastin®, and Herceptin®. These biologics are the most popular therapies in the world for their respective cancer and immune-disease indications, representing annual global revenue of more than $40 billion with more than $20 billion in the countries covered by this agreement. The partnership is planning to launch its first product by late 2016.

"This partnership is an important step toward introducing affordable, high-quality biotherapeutics to China.  Huahai is thrilled to partner with Oncobiologics, which brings us excellent biologics development and manufacturing capability, and a deep knowledge of the scientific and quality requirements within the developed world," said  Vice Chairman of Zhejiang Huahai and CEO of Huahai U.S., Mr. Jun Du .  "Through this partnership, we look forward to establishing a world class biologics operation in China while also participating in the very promising biosimilars market in the developed world."

"Huahai is a leader in small-molecule pharmaceuticals in China, and was the first company in China to receive finished product manufacturing approval from the US FDA.  They are distinguished by commercial strength in China and a deep quality culture in their operations, which is essential as we partner to create a strong biologics capability there," commented Oncobiologics Founder & CEO Pankaj Mohan , Ph.D.Mohan added, "Oncobiologics is fortunate to have a strong, experienced partner like Huahai as we work to launch these biosimilar assets to the world's most important commercial markets."

Financial terms were not disclosed.

About Zhejiang Huahai Pharmaceuticals Co., Ltd.
Zhejiang Huahai Pharmaceuticals Co., Ltd. was founded in 1989, and the company's stock was successfully listed in Shanghai Stock Exchange in March, 2003. The company produces finished dosage forms, APIs (Active Pharmaceutical Ingredients) and intermediates for both domestic and international markets. With total assets of 3,200 million yuan, the company has 11 subsidiaries in the United States, Shanghai, Hangzhou, and Linhai.  It occupies an area of 800,000 square meters, and has a staff of 3800. Huahai has been recognized as a National Key Hi-tech Enterprise, a National Pilot Enterprise of Innovation, a "State Certified Enterprise Technology Center" and is among China's top 500 private enterprises.  For more information, visit:  en.huahaipharm.com

About Oncobiologics, Inc.
Oncobiologics is a privately-held biopharmaceutical company developing a pipeline of biosimilars and next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Formed by a team of leading industry experts from firms such as Eli Lilly, Bristol-Myers Squibb, Amgen, Genentech, Merck and Pfizer, Oncobiologics operates from a state-of-the-art 30,000 sq. ft. R&D facility in Cranbury, NJ. For more information, please visit www.oncobiologics.com Contact:Rick GregoryDirector of Marketing & CommunicationsOncobiologics, Inc.rickgregory@oncobiologics.com 


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
2. SonaCare Medical Partners with University College London to Create Center of Excellence for HIFU Surgical Ablation Technology
3. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
4. MediPx Creates New Social Media Shopping Experience for Customers and Vendors
5. ATG Rehab and United Seating & Mobility Join Forces to Create Numotion
6. Recent Issue of Shape Magazine Creates Quite a Stir Over Growth Hormone
7. Hemp, Inc.s CEO, Bruce Perlowin, Announces Plan to Create a 500-Acre Kins Domain Community in Arizona
8. Domain Associates and Elite Consulting Collaborate to Create and Invest in Life Science Companies in China
9. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
10. ERISA Creates Benchmarking Challenges for Plan Sponsors
11. US Vitamin Injections Creates B12 Shot Category to Improve Visitor Experience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
Breaking Medicine News(10 mins):